ClosedBusiness2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices

MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity

Australian Government · Australia

This grant provides funding to organisations partnering with small to medium enterprises to accelerate promising drugs and devices into practice for cardiovascular disease and complications of diabetes. It is part of the Medical Research Future Fund and supports medical research, innovation and commercialisation.

Official Grant Page

Funding

Up to $15M

Location

Australia

Who Can Apply

Eligible organisations seeking to accelerate promising drugs and devices into practice Applicants are expected to partner with small to medium enterprises Projects must focus on cardiovascular disease and complications of type 1 or type 2 diabetes Funded organisations must support commercialisation and leverage co-funding from partners such as industry
Eligible organisations can apply for funding to accelerate into practice promising drugs and devices that reduce the burden of cardiovascular disease and complications of diabetes. The grant is designed for independent national organisation or organisations that will partner with small to medium enterprises. Successful organisations must target investment and related support through partnership projects, promote commercialisation of novel drugs and devices, provide a maximum of $1.5 million for each promising drug or device project, leverage support including co-funding from partner organisations such as industry, and provide a minimum investment of $3 million into each of cardiovascular disease, complications in people with type 1 diabetes, and complications in people with type 2 diabetes.

What's Funded

Funding supports national organisations to partner with SMEs and invest in promising drug development projects under topic A or device development projects under topic B for cardiovascular disease and diabetes complications. Activities include targeted investment, related support, partnership projects, and leveraging co-funding from industry and other partners.

Expected Outcomes

Expected outcomes include accelerated translation of promising drugs and devices into practice, commercialisation of novel cardiovascular and diabetes-related products, and minimum investment across cardiovascular disease, type 1 diabetes complications, and type 2 diabetes complications.

Key Information

Applicant Types

non_profituniversitycompanyother

Stage

established

Funding Purposes

researchinnovationcommercialisationr_and_d

Keywords

MRFFMedical Research Future FundTargeted Translation Research Acceleratorcardiovascular diseasediabetesdrugsdevicesmedical research

Frequently Asked Questions

What is the MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity?

The MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity is a business grant offered by Australian Government in Australia, providing Up to $15M in funding. This grant provides funding to organisations partnering with small to medium enterprises to accelerate promising drugs and devices into practice for cardiovascular disease and complications of diabetes. It is part of the Medical Research Future Fund and supports medical research, innovation and commercialisation.

How much funding does the MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity provide?

The MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity provides Up to $15M in funding.

Who is eligible for the MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity?

Eligible organisations seeking to accelerate promising drugs and devices into practice Applicants are expected to partner with small to medium enterprises Projects must focus on cardiovascular disease and complications of type 1 or type 2 diabetes Funded organisations must support commercialisation and leverage co-funding from partners such as industry

What activities are funded?

Funding supports national organisations to partner with SMEs and invest in promising drug development projects under topic A or device development projects under topic B for cardiovascular disease and diabetes complications. Activities include targeted investment, related support, partnership projects, and leveraging co-funding from industry and other partners.

How do I apply for the MRFF 2023 Targeted Translation Research Accelerator – Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity?

Start by checking your eligibility using the free Beta Docs eligibility checker. If eligible, Beta Docs' AI-powered platform can help you draft, review, and refine your application to maximise your chances of success.

Need help applying?

Beta Docs has helped founders secure $160M+ in competitive grants. Our AI platform drafts compliance-perfect applications — and our expert reviewers make sure you stand out.

Start with Beta DocsBook a free consultation